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Abstract
Background: Complete surgical resection of neoplasia remains one of the most efficient tumor therapies. However,
malignant cell clusters are often left behind during surgery due to the inability to visualize and differentiate them against
host tissue. Here we establish the feasibility of multicolor fluorescent intravital live microscopy (FILM) where multiple cellular
and/or unique tissue compartments are stained simultaneously and imaged in real time.
Methodology/Principal Findings: Theoretical simulations of imaging probe localization were carried out for three agents
withspecificityfor cancer cells,stromal host response,or vascular perfusion. This transport analysis gave insightinto the probe
pharmacokinetics and tissue distribution, facilitating the experimental design and allowing predictions to be made about the
localization of the probes in other animal models and in the clinic. The imaging probes were administered systemically at
optimal time points based on the simulations, and the multicolor FILM images obtained in vivo were then compared to
conventional pathological sections. Our data show the feasibility of real time in vivo pathology at cellular resolution and
molecular specificity with excellent agreement between intravital and traditional in vitro immunohistochemistry.
Conclusions/Significance: Multicolor FILM is an accurate method for identifying malignant tissue and cells in vivo. The
imaging probes distributed in a manner similar to predictions based on transport principles, and these models can be used
to design future probes and experiments. FILM can provide critical real time feedback and should be a useful tool for more
effective and complete cancer resection.
Citation: Thurber GM, Figueiredo JL, Weissleder R (2009) Multicolor Fluorescent Intravital Live Microscopy (FILM) for Surgical Tumor Resection in a Mouse
Xenograft Model. PLoS ONE 4(11): e8053. doi:10.1371/journal.pone.0008053
Editor: Giuseppe Chirico, University of Milano-Bicocca, Italy
Received August 31, 2009; Accepted October 30, 2009; Published November 30, 2009
Copyright:  2009 Thurber et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants P50 CA86355, U24 CA092782, and T32 CA079443. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Ralph Weissleder is a Shareholder at VisEn Medical. This is to confirm that the declaration does not alter the adherence to all the PLOS
ONE policies on sharing data and materials. It was merely listed because the authors purchased commercially available materials from a company for which
Weissleder has consulted.
* E-mail: rweissleder@mgh.harvard.edu
Introduction
Diagnostic decisions today are primarily based on molecular
markers, and there is continuous research and development of new
biomarkers that diagnose diseases more specifically, at an earlier
stage, and more rapidly[1]. In the case of cancer, complete
surgical resection of neoplasia remains one of the most efficient
therapies while postsurgical minimal residual disease has a
negative effect on long-term outcome[2]. In parallel, significant
advances in microscopy[3] are being applied to continuously
improve resolution at the subcellular level. One of the most
exciting applications of these advancements is to apply cellular
resolution imaging to in vivo settings to better understand biology in
its correct context (e.g. ‘‘intravital microscopy’’[4,5]) or for clinical
applications (e.g. ‘‘intraoperative imaging’’[6–8]).
Genetic markers and manipulation have deepened our
understanding of aberrant cancer signaling, growth, and prolifer-
ation[9]. Reporter genes involving various fluorescent proteins
have allowed the direct visualization of many cellular and
subcellular processes, and have opened the door to tracking
individual cells within tumors[10]. Such genetic markers have
been extremely powerful for experimental research. Unfortunate-
ly, they are not easily translated into the clinic, necessitating the
need for exogenous reporter probes. While there has been intense
interest in universal, highly specific tumor-seeking probes[10–13],
to date such probes for macroscopic imaging have largely
remained elusive. Therefore, FILM for surgical resection will
likely require microscopic imaging using a combination of
different probes to delineate both tumor and host tissue
compartments in the heterogeneous microenvironments found in
lesions[14] (figure 1A). While there are several setups being
explored for intraoperative imaging of tumor resection (e.g.
laparoscopic setup, hand held scanners), all of them involve the
ability of the surgeon to simultaneously or quickly image the
surgical field using fluorescent markers to identify healthy
structures and/or malignant tissue for resection. The molecular
markers increase the operator’s ability to visualize and remove the
tumors while sparing healthy tissue.
Several important questions must be addressed before applica-
tion of FILM to clinical settings. For example, what is the best
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etc.)? What are the kinetics of uptake, distribution, activation, and
clearance, and how will these translate to the clinic? What factors
dominate the background, and is the signal to background ratio
sufficient? Can we obtain cellular resolution in the clinic, and do
the in vivo results correlate with the current gold standards of
diagnosis? These questions must be answered before successful use
of FILM in the operating room.
To aid in surgical resection, imaging should be carried out intra-
operatively in real time to provide direct feedback to the operator.
The surgeon ideally would have a wide field of view to quickly
‘‘survey’’ the tissue, but should also be able to view suspicious
regions under higher magnification down to cellular resolution.
The imaging probes should target all malignant disease with a
sufficient signal to background ratio so that there is little ambiguity
between malignant and normal tissue. Ideally, these agents would
also identify locoregional metastases for resection. Finally, the
agents should be easy to administer so they are readily incorpo-
rated into surgical resection procedures.
Topically applied imaging agents have the advantage of using
significantly less probe and avoiding blood flow and extravasation
limitations (but not diffusion limitations) to transport. However,
diffusion of these molecules from the tissue surface to underlying
cells is extremely slow[15]. A macromolecule may take a day to
diffuse one millimeter from the surface[16]; therefore only exposed
superficial cells would be labeled, and lesions deeper in the tissue
would be missed. In contradistinction, systemic targeting is able to
reach these buried lesions, and timing is less of a concern. We
therefore decided to focus on imaging probes administered by
intravenous injection well in advance of a planned surgery where
the agents use the tumor and peritumor vasculature to transport
imaging probe throughout the tissue.
The imaging probes in this study were chosen to highlight three
main compartments in the tumor (figure 1B): cancer cells via an
epithelial antigen (CD326, EpCAM commonly used to detect
circulating cancer cells and overexpressed on a wide variety of
epithelial cancers[17]), functional supporting microvasculature (a
probe with prolonged distribution in the plasma volume), and
stromal tissue (easily targeted innate immune cells, such as the
CD11b pool). The antibody localization is based on binding and
retention in the tumor tissue, while the protease sensor contains
quenched fluorophores. Upon cleavage of the backbone, these
fluorophores are de-quenched, yielding a fluorescent signal. These
representative imaging agents and other similar molecules are
being studied for clinical translation[8,18–22].
This study was designed to address several questions about the
feasibility of multicolor FILM using both an experimental and
theoretical approach. We argued that the use of multiple markers
Figure 1. Characterization of Imaging Agents. A) Tumor schematic. B) Mechanisms of probe localization. Numbers indicate wavelength of
fluorescent channel. C) Imaging agent properties. MW=molecular weight, Ex=excitation maximum, Em=emission maximum. a and b are plasma
clearance rate constants, with A being the fraction of the a phase. D) Simulated time course of antibody and protease sensor localization. Tumor to
background ratios were estimated based on a characteristic normal tissue compartment. Different scales are used on the TBR axis.
doi:10.1371/journal.pone.0008053.g001
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conveying the location of neoplastic cells and necrosis, but also the
infiltration or encapsulation status of the border regions.
Results
Theoretical Analysis
To gain insight into the uptake and distribution of these imaging
agents and help interpret the data, a computational model based
on the mechanistic steps in transport was developed for each
probe. A more thorough understanding of imaging probe
localization and limitations provides guidance for how they may
be used, and when they may fail, in the clinic. This analysis
requires a systems level understanding of the pharmacokinetics,
from the whole body plasma clearance (figure 1C) to the molecular
and cellular kinetics. Both the antibody and protease sensor must
flow to the tumor in the blood, extravasate into the interstitium,
diffuse to their site of action, and then bind (in the case of
antibodies) or be activated (taken up by pinocytosis and cleaved in
the case of the protease sensor). The kinetic rate for each of these
steps for this particular antibody and protease sensor were
analyzed in the model (supplemental information S1). Using this
model for the tumor and normal tissue uptake, the concentration
and tumor to background ratios of the imaging agents were
simulated over time (figure 1D). Based on these simulations, the
imaging time points of 24 hours for the protease sensor (primarily
a marker for the CD11b(+) pool) and 72 hours for the tumor
antibody were chosen based on total signal. While the maximum
uptake was estimated after ,1 day for the antibody, there was
uncertainty in the internalization rate from the literature, with
slower rates yielding peak uptake at later times.
Based on theoretical considerations, a 30 mg/mouse dose for
this antibody and model is subsaturating even in these small, well
vascularized tumors. The plasma concentration (AUC) was not
quite sufficient to target all EpCAM, since the clearance modulus
was greater than one (figure 2A, table 1). A clearance modulus less
than one would indicate the antibody has sufficient time in the
plasma to extravasate and target all the tumor cells. Even with
slower clearance, the 15-hr half-life of internalization sequesters
enough antibody to prevent targeting of all antigens. A Thiele
modulus greater than unity signifies that the antibody turnover
(internalization and degradation) in the tissue is faster than the rate
at which antibody enters the tumor. Both of these values must be
less than one for saturation to occur[23].
With subsaturating doses, the antibody concentration in the
tumor has low sensitivity to the number of binding sites. To show
this, the antibody concentration in the tumors was simulated as a
function of the number of targets per cell. For these molecules,
blood flow, diffusion, and binding all occur much faster than
extravasation, which is the rate-limiting step in uptake[16]. Using
a combination of parameters measured in vitro and estimated
from the literature (supplemental information S1), the antibody
concentration in the tumors was simulated[23]. With a large
number of targets per cell, as with many cancer antigens (e.g.
EGFR, HER2/neu, CEA), the number of free binding sites
exceeds the number of antibodies entering the tissue. At this
subsaturating dose, the tumor concentration depends on the
extent (surface area) of functional blood vessels in the tissue and is
insensitive to the number of binding sites. In contrast, with a low
number of antigens per cell the tumor becomes saturated, and the
additional antibody that enters the tumor interstitium has no
free binding sites. It therefore clears from the tissue, and the
concentration becomes a function of the antigen density
(figure 2B). The transition between these two regimes is
dependent on multiple factors present in the clearance and
Thiele modulus.
The kinetics of a model protease sensor[24] localization were
also examined. These agents are taken up through pinocytosis by
the cell and cleaved, de-quenching their fluorescence. The probe
may also be activated by secreted proteases, but due to the high
Figure 2. Theoretical Localization. A) Dimensionless groups that
describe the fundamental limits to antibody uptake (clearance and
Thiele modulus) and protease sensor localization (cellular uptake
number). A clearance modulus or Thiele modulus greater than one
indicates the antibody is cleared from the plasma too rapidly or
internalized by the cells too quickly to saturate the tumor. A cellular
uptake number less than one means the protease sensor will localize
based on the local pinocytosis rate instead of vascular transport. B)
Antibody simulation. At subsaturating doses, antibody uptake is not
sensitive to target/antigen density. C) Protease sensor simulation. In
contrast to the antibody, the concentration is dependent on the
number of infiltrating macrophages, not the extent of vascularization.
doi:10.1371/journal.pone.0008053.g002
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that intracellular probe dominated the signal. Based on theoretical
estimates (supplemental information S1), the cleavage kinetics of
the probe are faster than cellular uptake by activated macrophag-
es, so the enzyme kinetics were ignored. With antibodies, the
antigen binding rate is much faster than diffusion, immobilizing
the antibody in a perivascular distribution. For the protease sensor,
the diffusion rate is faster than cellular uptake. The probe
therefore distributes more evenly in the tissue. In fact, the overall
rate of pinocytosis[25], which is a function of how many cells are
ingesting fluid in the tissue, is also slower than blood flow and
extravasation, as indicated by the cellular uptake modulus less
than one (figure 2A). This ratio of cellular uptake to vascular
transport indicates that pinocytosis is slower than delivery. The
uptake of the protease sensor is therefore a function of the fraction
of macrophages (which have a high phagocytosis rate) in the tissue
(figure 2C), with the uptake per cell being relatively constant, as
seen experimentally in other systems[26]. Only when macrophag-
es form 10 to 100% of the tissue does the uptake per cell start to
slow down due to limitations in extravasation of the probe.
The vascular probe used was a macromolecule imaged at early
time points following injection before the plasma concentration
drops due to redistribution in the tissue. Similar to the other
macromolecules, the blood flow rate in most vessels is faster than
extravasation for this agent, allowing the probe to fill the full
length of the vessel. Interstitial diffusion is also faster than
extravasation, so any probe that does leak out diffuses away from
the vessel, giving a clean outline.
Cellular Localization
After simulating the results, the technique was tested in a
subcutaneous colon cancer model. Using a 10X objective for
multicolor FILM, the vascular probe yielded well-delineated blood
vessels (figure 3A). The antibody localized primarily in clusters of
tumor cells, but it also resulted in a significant signal in the
surrounding stromal tissue (presumably host cells). The anti-
Table 1. Model Parameters.
Probe Parameter Symbol Typical Value
Antibody Antigen concentration [Ag] 1.7 mM
Antibody concentration [Ab] 100 nM
Vascular permeability P 3610
29 m/s
Blood vessel surface area to volume ratio S/V 100/cm
Biexponential clearance rate constants A 0.7
B 0.3
a 8610
26/s
b 1.1610
26/s
Antigen internalization rate constant ke 1.3610
25/s
Protease Sensor Fluid pinocytosis rate kpino 1.1610
25/s
Vascular permeability P 10
29 m/s
Blood vessel surface area to volume ratio S/V 200/cm
doi:10.1371/journal.pone.0008053.t001
Figure 3. Cellular Localization. A) Multichannel in vivo image of HT-29 tumor. The vascular probe outlines the blood vessels, anti-EpCAM antibody
labels tumor cells with some macrophage binding, and the protease sensor localizes to tumor macrophages. B) Histology of the samples with CD31
labeling blood vessels, anti-EpCAM labeling tumor cells, and Mac3 labeling tumor macrophages. The low magnification EpCAM image shows the
heterogeneous distribution of cells in the tumor.
doi:10.1371/journal.pone.0008053.g003
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Fc region, which helps increase plasma half-life through FcRn
interactions, also binds to several types of immune cells[27] when
injected intravenously (an important contradistinction to frozen
sections where this interaction can be blocked). Flow cytometry of
digested tumors indicated the stromal cells were primarily tumor-
associated macrophages, and the antibody bound to these cells ex
vivo (data not shown). However, the majority of retention occurred
due to EpCAM binding, since non-specific antibody controls had
drastically lower uptake. The protease sensor was localized
primarily in a thin palisade of tumor stromal cells. Further
analysis revealed that the probe accumulated preferentially in
macrophages due to the high cellular uptake rates and abundant
expression of cathepsin B[28]. Some cancer cell lines have been
shown to take up protease sensors[29], and this uptake has been
correlated with tumor aggressiveness[30]. This is not surprising
since cell growth and proliferation signaling networks are
connected to cellular trafficking[31]. Based on these results, the
moderately differentiated HT-29 cell line appeared to have a
lower cellular uptake compared to other experimental models.
The color FILM imaging results were compared with
immunohistochemical staining, the gold standard for tissue
pathology. Anti-CD31 staining showed vessels that were exclu-
sively located in the stroma, which stained primarily with a Mac3
antibody. The stromal tissue surrounded clusters of cancer cells,
which stained with an anti-EpCAM antibody (figure 3B).
Tumoral Heterogeneity
To address the issue of pan-tumoral distribution, color FILM
images of entire tumors were acquired with a 0.56X objective
(figure 4A). The different tumors (even within the same animal
when implanted into different sites) were highly heterogeneous due
to the stochastic nature of tumor cell growth, vascularization,
necrosis, stromal cell infiltration, etc. The antibody localized in a
heterogeneous pattern near the surface of the tumor, but with no
optical slicing, much of the signal was scattered from cells deeper
in the tissue. The protease sensor gave a moderate signal in the
middle of the tumor surrounded by an intense ring.
Histology at the surface of the tumor (figure 4B) showed a highly
vascularized, well-encapsulated tumor. The capsule stained
primarily with Mac3, indicating a high concentration of
infiltrating macrophages between the tumor cells and underlying
muscle. Based on CD31 staining, the blood vessel surface area to
tumor volume was ,260 cm
2/cm
3 in this outer region, whereas it
was ,120 cm
2/cm
3 in the middle of the tumor. The actual
disparity may be even larger, since CD31 staining does not
indicate which vessels are functional. The vascular probe showed
mostly functional vessels near the tumor surface, but vascular
collapse and poor blood flow may occur near the center. Based on
the theoretical simulations, however, the higher protease sensor
uptake in the ring-like pattern is due to the high macrophage
density in the capsule, not increased blood flow or extravasation in
the periphery.
Specificity
The signal-to-background ratio for these probes is important in
the intraoperative setting in order to distinguish cancerous cells
from healthy tissue. Region of interest analysis was done on 4
control mice and 5 experimental mice to compare tumor to
background levels. A large field of view is desirable for scanning
the surgical field, so a 0.14X objective was used for analysis
(6.3 cm by 4.7 cm field of view). The autofluorescence (no injected
Figure 4. Tumor Heterogeneity. A) Low magnification epifluorescence image of tumors. A skip lesion is highlighted with an arrow in tumor 3. B)
Histology of the tumor border showing a well vascularized ,200 mm thick tumor capsule between the underlying muscle (left) and tumor cells
(right).
doi:10.1371/journal.pone.0008053.g004
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infrared was similar (figure 5A). When mice were injected with
anti-EpCAM-680, the fluorescence signal increased dramatically
for the tumors, while non-specific uptake in healthy surrounding
tissue was minimal. The fluorescence ratio between tumor and
muscle after probe administration in the mice was 3.2 (figure 5B),
so the tumor could clearly be visualized against the background
tissue without any correction for autofluorescence. However, by
subtracting away the autofluorescence, the ratio between the
fluorophore in the tumor versus the muscle was 9 to 1. This is
reasonable compared with the predicted ratio of 13 from the
theoretical simulations based on fluorophore concentrations.
While the signal adjusted for autofluorescence gives the larger
contrast and more accurately reflects the specificity of the probe,
this adjustment becomes problematic with tissues that have widely
varying autofluorescence levels. Ideally, the level of autofluores-
cence would be known for a given tissue, allowing the baseline
signal to be adjusted accordingly.
The relationship between tumor-to-background ratios and
magnification is complex and a result of several factors. In
general, higher magnification yields better contrast due to
increased efficiency in exciting and capturing light with higher
numerical aperture lenses and lower partial volume/pixelation
effects in small metastases. With cellular resolution, contrast
between tumor cells and background increases further due to
cellular localization. While the background results from diffuse
unbound probe in the case of an antibody, specific binding on
tumor cells yields intense punctate labeling. With the optical
slicing ability of a laser-scanning microscope, the background of
out-of-focus light is also reduced. Tumor-to-background ratios
with cellular resolution in the laser scanning system are routinely
greater than 10 with no adjustments for autofluorescence,
compared to 3.2 with macroscopic imaging.
Discussion
Fluorescence imaging is expected to become a powerful adjunct
to traditional surgical oncologic therapies. To become a reality,
several technological advances and proof-of-principle studies are
necessary. These include instrumentation and visualization
techniques[8], imaging probes for human use[32], and preclinical
efficacy testing in different models. Several of these questions were
addressed in these experiments through the development of
multicolor FILM.
Clinical Requirements
The successful application of multicolor FILM for surgical
resection will require biocompatible and safe probes to clearly
identify malignant cells in vivo in real time. This is advantageous
over frozen sectioning by maintaining the exact spatial location of
the unresected cancer, rather than inferring the remainder of cells
at the surgical margins. Such cancer cells should ideally be
identifiable based on molecular markers of the disease, rather than
structural indirect information. Early results with intraoperative
imaging have shown successful identification of lesions that were
otherwise undetectable[33]. However, localization based on
structural abnormalities resulted in several false positives, high-
lighting the need for more specific imaging agents. While pan-
carcinoma markers, such as EpCAM, should target many cancers,
pre-operative biopsies could be used to identify appropriate
markers, similar to the indication for trastuzumab. Cell surface
antigens that are overexpressed at a high level with little to no
expression in normal tissues would be ideal targets, but expression
levels vary considerably among patients and even between lesions,
which is an additional reason why a multichannel approach of host
response was used in parallel.
Delivery
The agents used in this study were delivered systemically to
target malignant cells, host tissue infiltration, and the tumor
vasculature. While the ease of delivering a topical agent is
appealing, penetration of these agents is severely limited. Due to
the slow diffusion of molecules in tissue, the maximum penetration
depth would be a few hundred microns. An effective topical agent
would have to be able to be delivered quickly (i.e. minutes), so that
it could be re-applied several times after resection to verify clean
margins. On this time scale, high doses of macromolecule are
required to overcome the reduction in penetration due to binding.
At these doses, probe passively taken up by healthy tissue in the
interstitium or non-specifically bound is not able to be cleared
quickly, resulting in poor tumor to background ratios (data not
shown).
For the systemically delivered agents, transport simulations were
used to help design the experiments and make predictions on
distribution. These simulations showed that the antibody dose was
sub-saturating and therefore limited by delivery (vascular surface
area and permeability) rather than the number of binding sites.
While the antigen expression level does not have a large impact on
antibody signal with subsaturating doses, high antigen expression
is still ideal since it will yield a brighter signal when targeting small
metastases and single cells, which are more easily saturated. The
extravasation limited antibody uptake in tumors is in contrast to
the protease sensor, where cellular uptake was slower than
vascular delivery. In this case, the signal intensity is proportional
to the fraction of macrophages that are actively taking up the
sensor.
Using subsaturating doses of antibody, some cancer cells may
not be targeted, especially in poorly perfused regions. However,
Figure 5. Signal Intensity. A) Semi-quantitative epifluorescence of
antibody signal. The average intensity value for the ROI is reported with
the standard error. N=number of tumors. B) Tumor to background
ratios based on total signal intensity and background subtracted
signals.
doi:10.1371/journal.pone.0008053.g005
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the surface of tumors and micrometastases[35] ensure adequate
targeting of these critical border areas. In fact, a small skip lesion,
which could be missed in frozen sections, was easily visualized with
the antibody (figure 4, arrow).
The antibody gave a strong signal to background ratio, even at
subsaturating doses. In theory, the tumor to background ratio is
not dependent on the dose, since both signals are proportional to
the amount of probe injected. For example, doubling the dose will
double the tumor signal (prior to saturation) and double the non-
specific signal in normal tissue[36]. However, the instrument noise
and autofluorescence are constant, so the dose must be large
enough to yield a signal significantly higher than this background.
Achieving a signal above this autofluorescence is the main
limitation to lowering the dose. Antibodies maintain their
specificity even at doses 1000-fold lower than used here (e.g.
nanograms of radiolabeled antibody/mouse[37]), so methods to
reduce autofluorescence or amplify the signal (spectral deconvolu-
tion, up-converting fluorophores, click chemistry amplification,
etc.) could lead to lower required doses.
Magnification and Resolution
In the intraoperative setting, the operator must be able to image
the entire surgical field to identify tissue that needs to be resected.
The tumors were easily visualized with a low magnification
objective (0.14X) giving a field of view of 30 cm
2. However, after
resection, the border regions may be scanned at high magnifica-
tion to achieve cellular resolution. Instrumentation to quickly
switch to higher magnification objectives would be ideal to detect
any remaining cells at the surgical margins by allowing suspicious
areas to be examined more closely without requiring a time
consuming scan of the entire surgical field. The larger numerical
aperture of these higher magnification lenses is able to capture the
light more efficiently from the sample, detecting individual cells.
The laser scanning color FILM images in figure 3 illustrate the
distribution of the different probes without the diffuse background
from signal deeper in the tumor. While these images were taken at
the surface of the tumor, the optical slicing is likely not needed
when detecting a few isolated cells, for example at a positive
margin, since there will be little signal from deeper in the healthy
tissue. In the clinical setting, a diffuse signal could indicate a tumor
mass buried under healthy tissue. Detection of buried lesions
depends on several factors, such as the size of the tumor mass,
efficiency of probe uptake (e.g. vascularization), wavelength of
light, and type of tissue. At this point, it is not possible to detect a
few cells buried under millimeters or centimeters of tissue, but
microscopic imaging is able to detect cells at an exposed resection
margin. A number of fiberoptic systems with the above capabilities
are currently under development.
Multicolor Imaging
The systemically delivered agents were able to identify separate
compartments within the tumor. Color FILM using a 10X
objective showed the antibody was able to target cancer cells based
on expression of the epithelial cell lineage marker EpCAM, while
the vascular probe and protease sensor provided feedback on the
extent of vascularization[38,39] and stromal cell infiltration[40].
Although the malignant cells are an important target for resection
and can help distinguish tumor cells from inflamed tissue, the
other imaging agents put the antibody probe in context. Regions
devoid of antibody but also lacking vascular probe may indicate
poor blood flow and necrosis. This tissue can be resected to
remove any remaining viable cells in these hypoxic regions.
Depending on the tumor, malignant cells at the border regions
could be well encapsulated by stromal tissue or infiltrating into
healthy adjacent tissue as indicated by the protease sensor. The
latter case may require further inspection under higher magnifi-
cation to ensure adequate margins are taken. This information
would not be provided to the operator using single channel (black
and white) FILM.
Challenges
This study demonstrates the feasibility of color FILM for tumor
resection. Separate cancer cell, vascular, and stromal compart-
ments were imaged in vivo from the whole tumor to the cellular
level, and a signal to background ratio of 9 provided clear contrast
between malignant and healthy tissue. Several issues need to be
explored further before transitioning into the clinic. First, is the
tumor to background ratio sufficient in multiple types of cancer
with different antigens since the autofluorescence and expression
levels vary? Second, can images be taken at video frame rates,
allowing simultaneous imaging and resection? Are there problems
when dealing with different organ systems, such as imaging
internal body cavities or delivery to different tissues (e.g. crossing
the blood brain barrier)? Finally, will these probes be useful for
detecting lymph node metastases? These issues are currently being
examined with additional experiments.
In conclusion, real time, multicolor FILM is capable of
providing critical information on the location of malignant cells,
the status of border regions, and extent of local metastasis for
surgical oncology. Identification of malignant tissue can be done
instantaneously with the exact spatial location of residual cells
including skip lesions, advantages over frozen sectioning during
surgery. A computational model was developed to describe the
localization of these probes, and this model was used to help design
the experiments, interpret the results, and make predictions of
behavior in other systems. Multicolor FILM has the potential to
facilitate complete resection, obtaining negative surgical margins
to lower morbidity from local recurrence[2,41–43] and decrease
mortality[44].
Materials and Methods
In vivo Imaging
All animal experiments were carried out in accordance with
guidelines from the Massachusetts General Hospital Subcommit-
tee on Research Animal Care which serves as the institutional
animal care and use committee as required by the Public Health
service. Mice were maintained on a non-fluorescent diet
throughout all experiments. For the tumor mouse model, the
moderately differentiated human colon adenocarcinoma line HT-
29 (ATCC; Manassas, VA) which expresses 2–3 million EpCAM
per cell was used. Approximately 1.5 million cells were injected
subcutaneously in nude mice (Cox-7, Massachusetts General
Hospital, Boston, MA, USA). When the tumors reached 3–4 mm
in size, mice received 30 mg of anti-EpCAM antibody (R&D
Systems; Minneapolis, MN) conjugated to VT-680 dye (Visen;
Bedford, MA) by tail vein injection three days before imaging.
Antibodies contained approximately 2 dye per IgG. One day
before imaging, mice received 2 nmol of Prosense-750 (Visen;
Bedford, MA) via tail vein, and Angiosense-488 was administered
retro-orbitally immediately before imaging.
Mice were anesthetized with intraperitoneal injection of 90 mg/
kg ketamine and 10 mg/kg xylazine, and the skin covering the
tumor and surrounding muscle was removed. An Olympus IV-100
system (Olympus; Center Valley, PA) was used to image the
488 nm, 680 nm, and 750 nm channels in series using an
Olympus 10X/NA 0.4 objective. A metal stabilizer ring was
Color FILM for Tumor Resection
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Olympus OV-110 epifluorescence imager was used for whole
tumor imaging. The gain on the camera was set to zero and a
280 ms exposure time was used for semi-quantitative analysis.
Longer exposure times sometimes saturated the image, while
shorter exposures provided good contrast but did not use the full
dynamic range of the camera for quantification. Under the
conditions used, the fluorescence intensity was linearly propor-
tional to the dye concentration in controls (data not shown).
Tumor Characterization and Histology
The number of EpCAM binding sites per cell was measured
using flow cytometry with quantitative beads (Bangs Laboratories;
Fishers, IN) according to the manufacturer’s instructions. The
blood vessel surface area per tumor volume was estimated from
the CD31 stained slides using the method of Hilmas and
Gilette[45].
After imaging, tumors were flash frozen in OCT using
isopentane cooled with dry ice. The serial histology slices were
stained with an anti-EpCAM antibody (R&D Systems; Minnea-
polis, MN), Mac3 antibody (BD Pharmingen; Franklin Lakes, NJ),
and anti-CD31 antibody (BD Pharmingen; Franklin Lakes, NJ)
using standard protocols.
For flow cytometry on tumor cells, a protocol was adapted from
one previously described[46]. Briefly, the tumors were excised
from the mice, digested in 0.2 mg/mL collagenase IV (Sigma-
Aldrich) for 1 hr at 37uC, filtered through a 40 mm nylon mesh,
washed, and resuspended in PBS prior to analysis.
Supporting Information
Supplemental Information S1
Found at: doi:10.1371/journal.pone.0008053.s001 (0.87 MB
DOC)
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